Evidence map›Paper›PMID 37191353›Full record

ArticleMolecular pharmaceutics2023

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.

Outi Keinänen, Samantha M Sarrett, Samantha Delaney, Cindy Rodriguez, Eric J Dayts, Emily Capone, Frederic Sauniere, Rodolfo Ippoliti, Gianluca Sala, Stefano Iacobelli and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Ultra-low dose immunoPET usingFrontiers in medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Outi KeinänenDepartment of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.ORCID 0000-0002-3939-6706
Samantha M SarrettDepartment of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
Samantha DelaneyDepartment of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
Cindy RodriguezDepartment of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
Eric J DaytsDepartment of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.
Emily CaponeDepartment of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti 66100, Italy.
Frederic SauniereMediapharma srl, Chieti 66013, Italy.
Rodolfo IppolitiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila 67100, Italy.
Gianluca SalaDepartment of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti 66100, Italy.
Stefano IacobelliMediapharma srl, Chieti 66013, Italy.
Brian M ZeglisDepartment of Chemistry, Hunter College, City University of New York, New York 10021, New York, United States.ORCID 0000-0002-9091-744X
The Graduate Center, CUNY · USUniversity of Chieti-Pescara · ITCity University of New York · USMemorial Sloan Kettering Cancer Center · USUniversity of L'Aquila · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Pretargeted Clinical Imaging of CA19.9 in Pancreatic CancerU01CA221046 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ZEGLIS, BRIAN MATTHEW · 2018 to 2022
$3.5M
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-TrastuzumabR01CA204167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ULANER, GARY ALLAN · 2016 to 2020
$3.4M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
The Ivis Spectrum CT for Pre-Clinical Oncology ResearchS10OD016207 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2013 to 2013
$595k
SHARED INSTRUMENT: FOCUS MICROPET: CANCERS10RR020892 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2005 to 2005
$499k
Harnessing PET to Study the In Vivo Fate and Health Effects of Micro- and NanoplasticsK99ES034053 · NIEHS · HUNTER COLLEGE · PI KEINAENEN, OUTI MARIA · 2022 to 2022
$111k
Leveraging Metalloinsertors for the PET Imaging and Endoradiotherapy of MMR-Deficient CancersF31CA275334 · NCI · HUNTER COLLEGE · PI DELANEY, SAMANTHA PATRICIA · 2022 to 2023
$65k
NCI NIH HHS F31 CA275334NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204167NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS U01 CA221046NCRR NIH HHS S10 RR020892NIEHS NIH HHS K99 ES034053NIH HHS S10 OD016207
6 · The paper itself

Abstract

Galectin-3 binding protein (Gal-3BP) is a glycoprotein that is overexpressed and secreted by several cancers and has been implicated as a marker of both tumor progression and poor prognosis in melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and breast cancer. The expression of Gal-3BP by a variety of neoplasms makes it an enticing target for both diagnostics and therapeutics, including immuno-positron emission tomography (immunoPET) probes and antibody-drug conjugates (ADCs). Herein, we report the development,

Indexed as

Carcinoma, Non-Small-Cell LungImmunoconjugatesLung NeoplasmsMelanomaAnimalsAntigens, NeoplasmCell Line, TumorDeferoxamineExtracellular Matrix ProteinsGalectin 3GlycoproteinsHumansMicePositron-Emission TomographyZirconiumAntigens, NeoplasmDeferoxamineExtracellular Matrix ProteinsGalectin 3GlycoproteinsImmunoconjugatesLGALS3BP protein, humanPpicap protein, mouseZirconiumantibody-drug conjugategalectin-3 binding proteinimmunoPETpositron emission tomographytheranostic imagingZr-89

Identifiers

PMID37191353
PMCPMC10245371
OpenAlexW4376643595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.